文献速递基础与转化研究新药、器械与细胞基因治疗研发

弹性纳米结构生物分析微针纵向监测临床前肾脏与肝脏药物清除及功能障碍

Resilient nanostructured bioanalytic microneedle longitudinally monitors preclinical renal and hepatic drug clearance and dysfunction.
PubMed 文献 · Sci Transl Med · 2026-04-01

研究开发了一种双层工艺制备的弹性纳米结构生物电极微针,在兆帕级硬度组织中抗磨损,将大鼠体内生物传感器寿命延长至6天。结合血液-组织液平衡框架,该微针可准确推导血液等效药代动力学参数,实现窄治疗指数药物精准给药及肝肾清除直接评估,并在肝损伤和慢性肾病模型中检测到药物清除延迟与早期肾功能损害。

要点

  • RNB微针在大鼠体内实现6天药代监测,抗组织磨损且信噪比高。
  • 基于血液-组织液平衡可推导血液等效药代参数,评估肝、肾清除。
  • 在肝损伤模型中发现伊立替康清除延迟,肾损伤检测早于常规标志物阈值。

核心结论

  • RNB微针平台可实现微创、纵向监测低浓度分析物并实时评估器官功能。

研究设计与样本

  • 采用双层工艺制备微针基弹性纳米结构生物电极,以微米厚金黏附层增强电极并通过受控脱合金降低制备应力。
  • 在自由活动大鼠体内评估生物传感器寿命,并结合血液-组织液平衡框架推导血液等效药代参数。

主要发现

  • RNB将大鼠体内药代监测的生物传感器寿命延长至6天。
  • 在肝损伤模型中,RNB揭示化疗药伊立替康清除延迟。
  • 在肾病研究中,RNB记录与不同慢性肾病严重程度的血液抗生素药代相关。
  • RNB通过药物清除量化比常规生物标志物阈值更早检测到肾功能损害,并捕捉治疗干预下的恢复。

临床怎么用

  • 可用于窄治疗指数药物的精准给药监测。
  • 可微创纵向评估肝脏与肾脏药物清除功能。
  • 可在常规生物标志物阈值前提示肾功能损害并监测治疗恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wearable microneedle biosensors promise real-time molecular monitoring for precision medicine but are limited by low sensitivity and tissue abrasion. Overcoming these challenges, we recast electrode functionality not merely as a sensing substrate but as a mechanism for resilient, high signal-to-noise ratio (SNR) measurements in tissue. Our microneedle-based resilient nanostructured bioelectrode (RNB) is fabricated using a bilayer process that strengthens the electrode with a micrometer-thick gold adhesion layer and reduces fabrication-induced stress through controlled dealloying. The resulting RNBs are corrosion resistant, stable over a wide potential window, and have an artifact-free, nanocavity-textured interface. They integrate receptor-based electrochemical biosensors with enhanced SNR through increased active area, diffusion, and antifouling while remaining abrasion immune in megapascal-stiff tissues. The RNB extended in vivo biosensor lifetime for pharmacokinetics monitoring to 6 days in a freely moving rat. Paired with a blood-interstitial fluid equilibrium-based bioanalytical framework, the RNB accurately derived blood-equivalent pharmacokinetic parameters, enabling not only precision dosing of narrow therapeutic index drugs but also the direct assessment of hepatic and renal clearance. In hepatic studies, the RNB revealed delayed clearance of a chemotherapeutic (irinotecan) in liver-damaged models. In renal studies, RNB recordings correlated with blood antibiotic pharmacokinetics across chronic kidney disease severities. The RNB detected renal impairment earlier than conventional biomarker thresholds through drug clearance quantification and captured recovery under therapeutic intervention. These results establish the RNB as a viable microneedle platform for high-fidelity in vivo deployment of electrochemical biosensors, enabling minimally invasive, longitudinal monitoring of low-concentration analytes and real-time assessment of organ function.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Zhu J, Cheng X, Bahramian M, et al. Resilient nanostructured bioanalytic microneedle longitudinally monitors preclinical renal and hepatic drug clearance and dysfunction. Sci Transl Med. 2026. PMID: 41920968. doi:10.1126/scitranslmed.adr5493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。